Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (May 2020)
25 slides from Avicanna's investor presentation, May 11, 2020
Slide 1: A leader in biopharmaceutical advancements with natural cannabinoids
A leader in biopharmaceutical advancements with natural cannabinoids Avicanna.com TSX: AVCN OTCQX: AVCNF FSE: 0NN May 2020
Slide 2: Forward-Looking Statement
Forward-Looking Statement This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certain
Slide 3: Corporate Overview
Corporate Overview Delivering Cannabinoid Products Through Science Avicanna is a vertically-integrated biopharmaceutical company developing, manufacturing and commercializing various cannabinoid-based products for the global market place including: Genetics Active Pharmaceutical and seed program Ing
Slide 4: Corporate Overview
Corporate Overview Delivering Cannabinoid Products Through Science Multi-national R&D, pre-clinical and clinical platform 20+ scientists and clinicians housed in four federally licensed cannabinoid research laboratories Collaborations with world class academic and clinical institutions including the
Slide 5: Global Leader in Advanced Cannabinoid Research and Pharmaceutical Development
Global Leader in Advanced Cannabinoid Research and Pharmaceutical Development R&D Headquarters at JLABS in the MaRS Discovery District of Toronto Cannabis Research Licence issued by Health Canada to Avicanna at JLABS, the world’s largest urban innovation hub, where Avicanna’s scientists conduct rese
Slide 6: World-Class and Sustainable Value Chain: Cultivation, Production, and Manufacturing
World-Class and Sustainable Value Chain: Cultivation, Production, and Manufacturing 2 Fully Licensed Extraction, Manufacturing Cultivation Production, Subsidiaries and Purification Santa Marta Golden Hemp In-house extraction and Exclusive contract S.A.S.and Sativa Nativa isolation infrastructure man
Slide 7: Federally registered commercial genetics of hemp and cannabis in Colombia
• 30 federally registered commercial genetics of hemp and cannabis in Colombia • A scientific approach to breeding and optimization in collaboration with University of Guelph • A rich catalogue of 100’s of rare genetics from around the world that have been specially selected for the Avesta program •
Slide 8: Cannabinoid Formulations, Active Pharmaceutical Ingredients
Cannabinoid Formulations, Active Pharmaceutical Ingredients 09
Slide 9: Commercial Colombian Cultivation Projects
2 Commercial Colombian Cultivation Projects The Micro-climate of Santa Marta and the Foothills of the Sierra Nevada Mountains: Optimal Environmental Conditions • 480,000 square feet of combined cannabis cultivation and capacity to produce 30,000 kg a year • USDA National Organic Program certified •
Slide 10: Extraction, Production, Purification, and Manufacturing
Extraction, Production, Purification, and Manufacturing Exclusive Partnership High Quality Pharmaceutical Grade Global GMP Certifications API and Bulk Formulations • ANVISA (Brazil) Utilizing proprietary extraction and purification • DIGMID (Perú) processes in line with GMP standards and full • EU •
Slide 11: Consumer and Retail Derma-cosmetic Products
Consumer and Retail Derma-cosmetic Products PRODUCT LAUNCH EXPECTATIONS*: Colombia Q419 • EU 1H20 • USA 1H20 • Canada 2H20 11 *The product launch expectations are conditional upon regulatory approvals
Slide 12: About Pura Earth
About Pura Earth CBD Derma-cosmetics With completed clinical trials for derma-cosmetic formulations to support and improve the health and appearance of the skin. At Pura Earth we believe in the power of nature to enhance the health and appearance of skin, and in the power of science to amplify these
Slide 13: Completed Cosmetic Clinical Trials
Completed Cosmetic Clinical Trials Anti-aging Serum Overview Results • Study Design: 1 arm, n=54 • Sustained hydration* End Points • Fast hydration • Primary endpoint: Evaluation (visual) in the improvement • Maintains a normal and healthy pH of the skin of fine lines& dark spots associated with agi
Slide 14: Medical and Rx products
Medical and Rx products PRODUCT LAUNCH EXPECTATIONS*: USA (California) 4Q19** • Colombia 1H20 • Canada 1H20 • UK 1H20 • Australia 1H20 *The product launch expectations are conditional upon regulatory approvals **RHO Phyto products were launched in California through a license agreement with the Cali
Slide 15: RHO Phyto – Medical Cannabis 2.0
RHO Phyto – Medical Cannabis 2.0 Exclusive distribution agreement with Medical Cannabis by ShoppersTM Shoppers Drug Mart is Canada's leading drug store retailer with more than 1,300 pharmacist-owned locations from coast to coast About Medical Cannabis by ShoppersTM Medical Cannabis by ShoppersTM pro
Slide 16: RHO Phyto – Medical Cannabis 2.0
RHO Phyto – Medical Cannabis 2.0 Pre-clinical data demonstrating superior bio-availability in collaboration with University of Toronto • Medical only - Prescription through practitioners • Pharmaceutical sales approach Organic and sustainable source of natural cannabis, formulated into cannabinoid-b
Slide 17: RHO Phyto – Products and Bio-availability Results
RHO Phyto – Products and Bio-availability Results 1400 Key pre-clinical findings* CBD Plasma Conc (ng/mL) 1200 Sprague Dawley rats were dosed once Soft Gel Capsules: with 19.3 mg/kg CBD orally via gavage 1000 Peak Plasma Sample Tmax High Bioavailability 800 Concentration (ng/mL) MCT-CBD Isolate 92 0
Slide 18: Pharmaceutical and Indication Specific Products with a Focus on Neurology, Pain, and Dermatology
Pharmaceutical and Indication Specific Products with a Focus on: Neurology, Pain, and Dermatology 18
Slide 19: Pharmaceutical Pipeline, Active and Target Areas
Pharmaceutical Pipeline, Active and Target Areas Pharmaceutical product pipeline following the traditional drug discovery and development process for eventual submission to the applicable government agencies, such as Health Canada, FDA (United States) and INVIMA (Colombia) Dermatology Psychiatry • E
Slide 20: Clinical Trials
Clinical Trials All Clinical Trials Pre-Clinical Protocol Protocol Ethics Clinical Development Established Approval Study Cosmetic Trials Eczema Prone Skin Complete Acne Prone Skin Complete Anti-Aging Complete Oral Care Mouthwash Pending Approval Real-World Evidence (RHO Phyto) Opioid Sparing Pendin
Slide 21: Financial Highlights
Financial Highlights Common Shares*: 26,387,444 • Fully diluted: 31,969,980 • Free Float: 6,613,400 • Director Escrow: 7,168,302** • Officers Escrow: 540,743** • 39 Month Escrow: 2,209,450*** Market cap $51.45, at market close on May 8th 2020 ($1.95)**** Last Financing (April 2020): $2.56M | $0.80 P
Slide 22: Executive Management Team
Executive Management Team Aras Azadian, M.Mgmt Dr. Amza Ali, MD, FRCP, MBA Chief Executive Officer Chief Medical Officer Aras brings extensive senior management experience in the biotechnology Dr. Ali is certified in Neurology by the Federation of Royal Colleges of and financial sectors including hi
Slide 23: Board of Directors / Senior Scientific Team
Board of Directors Aras Azadian, M.Mgmt Benjamin Leavenworth Chief Executive Officer Director Mr. Leavenworth has more than 20 years' experience in international business, with a focus on Latin America. Mr. Leavenworth is currently the Chief Strategy Officer of Afina International LLC ("Afina"), Set
Slide 24: Major Milestones
Major Milestones 3Q19 4Q19 Expected Upcoming Milestones* IPO on the TSX senior Organic (USDA) certification exchange as an R&D issuer Retail and e-commerce launch 1H20 2H20 Canadian Cannabis Research of Pura Earth in Colombia Licence issued at MaRS Agreement with Medical Cannabis • Phase II expansio
Slide 25: ir@avicanna.com
ir@avicanna.com +1 647-243-5283